Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

435
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
435
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.7K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

256
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
256
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

191
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
191
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

229
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
229
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

284
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
284

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LSD1 inhibition ameliorates congenital dyserythropoietic anemia type II.

Science translational medicine·2026
Same author

Development of a Patient-Specific Finite Element Analysis for Uncemented Total Hip Arthroplasty: A Step Towards Objective Surgical Planning.

Annals of biomedical engineering·2026
Same author

Navigating cardiovascular imaging fellowships.

Heart (British Cardiac Society)·2025
Same author

Reference Intervals for Ceruloplasmin Should Account for Age, Sex, Method, and Local Population.

The journal of applied laboratory medicine·2025
Same author

The frequently impaired health of leaders of nuclear weapon states: an analysis of 51 deceased leaders.

BMC research notes·2025
Same author

Guidelines for reproductive genetic carrier screening for cystic fibrosis, fragile X syndrome and spinal muscular atrophy.

Pathology·2025

Related Experiment Video

Updated: Sep 1, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K

COVID-19: Acing the Treatment.

Jez Hunter1, Puskar Bura2, Richard King2

  • 1Department of Anaesthetics and Intensive Care Medicine, Royal Cornwall Hospital, Treliske, Truro, UK.

Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre
|August 15, 2022
PubMed
Summary

Angiotensin converting enzyme 2 (ACE2) is crucial for SARS-CoV-2 cell entry, potentially worsening lung injury. However, ACE2-targeting therapies may offer survival benefits in COVID-19 patients.

Keywords:
Angiotensin II receptor blockersAngiotensin converting enzyme inhibitorsCOVID-19Novel treatmentsRenin-angiotensin-aldosterone system

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots
11:11

Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots

Published on: February 11, 2022

4.6K

Related Experiment Videos

Last Updated: Sep 1, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots
11:11

Efficient SARS-CoV-2 Quantitative Reverse Transcriptase PCR Saliva Diagnostic Strategy utilizing Open-Source Pipetting Robots

Published on: February 11, 2022

4.6K

Area of Science:

  • Cardiovascular Science
  • Infectious Disease
  • Pulmonology

Background:

  • SARS-CoV-2 utilizes Angiotensin Converting Enzyme 2 (ACE2) as its cellular receptor, triggering inflammatory responses and acute lung injury.
  • The Renin-Angiotensin-Aldosterone System (RAAS) plays a complex role in COVID-19, with potential for both detrimental and beneficial effects.
  • Early concerns about ACE inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs) in COVID-19 have been scientifically refuted.

Discussion:

  • ACEi and ARBs may provide a survival advantage for patients with COVID-19.
  • Understanding the intricate mechanisms of the RAAS in viral infections is critical for therapeutic development.
  • The biological plausibility of RAAS modulation warrants further investigation for novel treatment strategies.

Key Insights:

  • ACE2 is the key entry point for SARS-CoV-2 into host cells.
  • RAAS-modulating drugs like ACEi and ARBs show potential therapeutic benefits in COVID-19.
  • Continued research into RAAS pathways is essential for managing viral pandemics.

Outlook:

  • Developing new treatments targeting the ACE2-SARS-CoV-2 interaction is crucial.
  • Future research should focus on the long-term implications of RAAS modulation in viral infections.
  • Proactive strategies are needed to combat emerging variants and future pandemic waves.